National Research Corporation (NRC) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $17.04. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of NRC = $53.87 (+216.1% from the current price, the stock appears undervalued).
Valuation: NRC trades at a trailing Price-to-Earnings (P/E) of 31.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.22.
Financials: revenue is $137M, -3.2%/yr average growth. Net income is $12M, growing at -25.3%/yr. Net profit margin is 8.4% (thin). Gross margin is 56.3% (-6.1 pp trend).
Balance sheet: total debt is $79M against $14M equity (Debt-to-Equity (D/E) ratio 5.65, leveraged). Current ratio is 0.55 (tight liquidity). Debt-to-assets is 58.6%. Total assets: $135M.
SharesGrow 7-Criteria breakdown: Value 73/100 (Pass), Growth 15/100 (Fail), Past 100/100 (Pass), Health 17/100 (Fail), Moat 43/100 (Fail), Future ?/100 (Fail), Income 45/100 (Partial).
